Hunter C Smith
CIK 1636385 · Chief Financial Officer · last filed 2026-05-20
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$13.50M
Companies
4
Total Filings
81
Lifetime Open-Market Net
-$12.80M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RYTM | Chief Financial Officer | 119,611 | $112.84 | $13.50M | -$12.80M | 45 | 2026-05-20 |
| Spyre Therapeutics, Inc. (AGLE) Delisted | Director | — | $12.01 | — | $0 | 3 | 2023-06-30 |
| GENESEE & WYOMING INC (GWR) Delisted | Director | 0 | — | — | $0 | 22 | 2019-12-30 |
| GENESEE & WYOMING INC (GWRU) Delisted | Director | 1,226 | — | — | $0 | 3 | 2015-07-02 |
Recent Filings · Page 4 of 9
81 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-06-30 | Spyre Therapeutics, Inc. (AGLE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-21 | RYTM | Exer (M) | +2,000 | $13.8K | EDGAR |
| 2023-02-14 | RYTM | Mixed | +1,642 | -$18.9K | EDGAR |
| 2023-02-14 | RYTM | Sell (S) | −1,413 | -$38.9K | EDGAR |
| 2023-02-13 | RYTM | Mixed | +2,665 | -$38.7K | EDGAR |
| 2023-02-03 | RYTM | Grant (A) | — | $0 | EDGAR |
| 2022-12-29 | RYTM | Gift (G) | −2,500 | $0 | EDGAR |
| 2022-07-06 | RYTM | Mixed | +17,453 | -$30.8K | EDGAR |
| 2022-06-09 | Spyre Therapeutics, Inc. (AGLE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-02-15 | RYTM | Mixed | +1,511 | -$5.1K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.